The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer

被引：0

作者：

Makiyama, A. ^{[1
]}

Arimizu, K. ^{[1
]}

Hirano, G. ^{[1
]}

Makiyama, C. ^{[1
]}

Matsushita, Y. ^{[2
]}

Shirakawa, T. ^{[3
]}

Ohmura, H. ^{[4
]}

Komoda, M. ^{[4
]}

Uchino, K. ^{[4
]}

Inadomi, K. ^{[5
]}

Kusaba, H. ^{[6
]}

Shinohara, Y. ^{[7
]}

Kuwayama, M. ^{[7
]}

Kajitani, T. ^{[7
]}

Esaki, T. ^{[8
]}

Baba, E. ^{[9
]}

机构：

[1] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan

[2] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan

[3] Miyazaki Prefectural Miyazaki Hosp, Miyazaki, Japan

[4] Natl Hosp Org Kyushu Med Ctr, Dept Med Oncol, Fukuoka, Japan

[5] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Japan

[6] Kyushu Univ, Dept Med & Biosyst Sci, Fukuoka, Japan

[7] Kyushu Natl Canc Ctr, Fukuoka, Japan

[8] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan

[9] Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Japan

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-171

引用

页码：51 / 51

页数：1

共 50 条

[1] Clinical Complete Response of Recurrent Gastric Cancer after Third-line CPT-11 Chemotherapy
Hayashi, Masato
Fujita, Takeshi
Matsushita, Hisayuki
KEIO JOURNAL OF MEDICINE, 2023, 72 (02): : 60 - 64
[2] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
Makiyama, Akitaka
Arimizu, Kohei
Hirano, Gen
Makiyama, Chinatsu
Matsushita, Yuzo
Shirakawa, Tsuyoshi
Ohmura, Hirofumi
Komoda, Masato
Uchino, Keita
Inadomi, Kyoko
Arita, Shuji
Ariyama, Hiroshi
Kusaba, Hitoshi
Shinohara, Yudai
Kuwayama, Miyuki
Kajitani, Tatsuhiro
Oda, Hisanobu
Esaki, Taito
Akashi, Koichi
Baba, Eishi
GASTRIC CANCER, 2018, 21 (03) : 464 - 472
[3] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
Akitaka Makiyama
Kohei Arimizu
Gen Hirano
Chinatsu Makiyama
Yuzo Matsushita
Tsuyoshi Shirakawa
Hirofumi Ohmura
Masato Komoda
Keita Uchino
Kyoko Inadomi
Shuji Arita
Hiroshi Ariyama
Hitoshi Kusaba
Yudai Shinohara
Miyuki Kuwayama
Tatsuhiro Kajitani
Hisanobu Oda
Taito Esaki
Koichi Akashi
Eishi Baba
Gastric Cancer, 2018, 21 : 464 - 472
[4] CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians
Lim, WT
Lim, ST
Wong, NS
Koo, WH
JOURNAL OF CHEMOTHERAPY, 2003, 15 (04) : 400 - 405
[5] Clinical impact of oral intake in third-line treatment for advanced gastric cancer
Ogata, T.
Narita, Y.
Kumanishi, R.
Nakazawa, T.
Matsubara, Y.
Kato, K.
Nozawa, K.
Honda, K.
Masuishi, T.
Bando, H.
Kadowaki, S.
Ando, M.
Tajika, M.
Muro, K.
ANNALS OF ONCOLOGY, 2020, 31 : S141 - S141
[6] Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
Cui, Qingli
Mao, Yuefeng
Wu, Daoyuan
Hu, Yanhui
Ma, Dongyang
Zhang, LiHan
Liu, Huaimin
FRONTIERS IN ONCOLOGY, 2022, 12
[7] A retrospective analysis of third-line treatment in advanced gastric cancer.
Ishizuka, Yasunobu
Terazawa, Tetsuji
Yukami, Hiroki
Yamaguchi, Toshifumi
Kuwakado, Shin
Kii, Takayuki
Goto, Masahiro
Higuchi, Kazuhide
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[8] Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer
Liu, Liya
Yu, Hao
Huang, Lihong
Shao, Fang
Bai, Jianling
Lou, Donghua
Chen, Feng
OncoTargets and Therapy, 2015, 8 : 921 - 928
[9] Irinotecan (CPT-11) as first line treatment of patients with not pretreated advanced colorectal cancer
Firyida, JL
Menendez, MD
Mel, JR
Diz, P
Constenla-Figueiras, M
Casal, J
Valladares, M
Castellanos, J
Balcells, M
ANNALS OF ONCOLOGY, 1998, 9 : 38 - 39
[10] CPT-11 is an active agent in patients with advanced gastric cancer.
Köhne, CH
Catane, R
Klein, H
Peretz, T
Preusser, P
Niederle, N
Ducreux, M
Wilke, H
Jacques, C
CLINICAL CANCER RESEARCH, 1999, 5 : 3773S - 3773S

← 1 2 3 4 5 →